Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-COVID-19 dimeric antigen receptor T-cell therapy - Sorrento Therapeutics

Next Previous
Drug Profile

Anti-COVID-19 dimeric antigen receptor T-cell therapy - Sorrento Therapeutics

Alternative Names: Anti-COVID-19 DAR-T-cell therapy - Sorrento Therapeutics; Anti-COVID-2019 DAR-T-cell therapy - Sorrento Therapeutics

Latest Information Update: 28 Mar 2024

Print Profile Download Citation

At a glance

  • Originator Sorrento Therapeutics
  • Class Antivirals; Cell therapies; Fab fragments; Gene therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported COVID 2019 infections

Most Recent Events

  • 28 Mar 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in USA (Parenteral)
  • 31 Mar 2020 Sorrento Therapeutics enters into a research agreement with University of Texas Medical Branch for preclinical testing for COVID-2019 therapeutics
  • 27 Feb 2020 Preclinical trials in COVID-2019-infections in USA (Parenteral)

Development Overview

Introduction

Anti-COVID-19 dimeric antigen receptor T (DAR-T) cell therapy is being developed by Sorrento Therapeutics for the treatment of COVID-2019 infection. The cell therapy is based on the company's proprietary non-viral vector Knock out/knock in (KOKI) technology and is derived from the G-MAB antibody library. Preclinical development is underway in the US.

Sorrento Therapeutics believes that the KOKI DAR-T technology offers a number of advantages over virus based technology's including site-specific integration, enhanced clonal expansion and a streamlined transgene construct production. By using healthy donor T cells, the technology avoids reliance on the patient’s T cells, thus avoiding treatment delays and supporting reduced manufacturing costs ultimately overcoming some drawbacks of the CAR-T therapy. In DAR-T therapy, Sorrento Therapeutics has incorporated fab fragments in the construct, instead of ScFV.

As at March 2024, no recent reports of development had been identified for preclinical development in COVID-2019-infections in USA (Parenteral).

Company Agreements

In March 2020, Sorrento Therapeutics entered into a research testing agreement with the University of Texas Medical Branch at Galveston for the preclinical testing of Sorrento’s COVID-19 therapeutic product candidates. The testing will be performed at the University of Texas Medical Branch where most recently a COVID-19 viral isolate was obtained and the infection cell model for the SARS-CoV-2 virus was established. University of Texas Medical Branch will be advancing Sorrento’s proprietary COVID-19 product candidates. [1]

Key Development Milestones

Preclinical development is underway in the US [2] .

Patent Information

Sorrento Therapeutics has filed a patent application no. WO 2019 173 837A1 covering ‘Dimeric antigen receptors (DAR)’ [3] .

Drug Properties & Chemical Synopsis

  • Route of administration Parenteral
  • Formulation unspecified
  • Class Antivirals, Cell therapies, Fab fragments, Gene therapies
  • Target T lymphocyte
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • WHO ATC code

    V03A-X (Other therapeutic products)

  • EPhMRA code

    V3X (All Other Therapeutic Products)

Development Status

Summary Table

Download Data (CSV)
Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - - No development reported (Preclinical) USA Parenteral / unspecified Sorrento Therapeutics 28 Mar 2024

Commercial Information

Involved Organisations

Organisation Involvement Countries
Sorrento Therapeutics Originator USA
Sorrento Therapeutics Owner USA
University of Texas Medical Branch Collaborator USA

Development History

Event Date Update Type Comment
28 Mar 2024 Phase Change - No development reported No recent reports of development identified for preclinical development in COVID-2019-infections in USA (Parenteral) Updated 28 Mar 2024
31 Mar 2020 Licensing Status Sorrento Therapeutics enters into a research agreement with University of Texas Medical Branch for preclinical testing for COVID-2019 therapeutics [1] Updated 07 Apr 2020
27 Feb 2020 Phase Change - Preclinical Preclinical trials in COVID-2019-infections in USA (Parenteral) [2] Updated 12 Mar 2020
27 Feb 2020 Trial Update Sorrento Therapeutics plans a clinical trial for COVID-2019 infections in USA [2] Updated 12 Mar 2020
11 Mar 2019 Patent Information Sorrento Therapeutics files for patent protection for dimeric antigen receptors [3] Updated 12 Mar 2020

References

  1. SORRENTO AND THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON ENTER INTO PRECLINICAL TESTING AGREEMENT FOR COVID-19 THERAPEUTIC CANDIDATES.

    Media Release

  2. Sorrento to Provide Corporate Update, Including DAR-T Cell Therapy Advances, at LEERINK Global Healthcare Conference.

    Media Release

  3. Dimeric antigen receptors (dar) patent. Internet-Doc 2020;.

    Available from: URL: https://patents.google.com/patent/WO2019173837A1/en
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG
Legal
Back to top